arrow_back Trending Legislation
Share share

US-Israel Health Innovation: New Medicines and Medical Technologies.

This act establishes a cooperation program between the US and Israel to develop new health products and services, such as medicines, medical devices, and telemedicine. Through this program, citizens may gain access to innovative treatments and better healthcare in the future, as well as safer and more accessible biological products.
Key points
Support for research into new medicines, vaccines, and medical technologies, potentially improving treatment access and quality.
Development of telemedicine and digital health solutions, facilitating remote access to medical care.
Strengthening the security of biological product supply chains to prevent market shortages.
Potential for new job creation in the medical technology and pharmaceutical sectors.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
BIRD Health Act of 2025
Print number: HR 4473
Sponsor: Rep. Weber, Randy K. Sr. [R-TX-14]
Process start date: 2025-07-16
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about US-Israel Health Innovation: New Medicines and Medical Technologies.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 4473.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-07-16.

What are the main provisions?

Key points include:

  • Support for research into new medicines, vaccines, and medical technologies, potentially improving treatment access and quality.
  • Development of telemedicine and digital health solutions, facilitating remote access to medical care.
  • Strengthening the security of biological product supply chains to prevent market shortages.
  • Potential for new job creation in the medical technology and pharmaceutical sectors.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Weber, Randy K. Sr. [R-TX-14].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

Analysis and Potential Impact of HR 4473

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Public Investments Economy